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Abstract
Acute kidney injury (AKI) is a common complication in several settings inside 
and outside hospitals. It affects millions of people around the world, and despite 
high levels of research funding, there is no specific treatment that changes the 
disease course. The basis for unfavorable outcomes related to this disease is the 
failure to provide early diagnosis. Currently, the diagnosis of AKI is based on serum 
creatinine and urine output, and both measures have several limitations, making 
early diagnosis difficult. In recent decades, several biomarkers of kidney injury 
have been proposed, with neutrophil gelatinase-associated lipocalin (NGAL) being 
one of most studied and promising for use in early diagnosis. Despite there being 
several studies on NGAL, it has not yet been applied in clinical practice; thus, 
furthering the understanding of the development, interpretation, and limitations 
of NGAL in the diagnosis of AKI is the objective of this chapter.
Keywords: acute kidney injury, biomarkers, neutrophil gelatinase-associated 
lipocalin
1. Introduction
Acute kidney injury (AKI) is a frequent complication in several clinical settings, 
including large surgeries [1], emergency departments [2, 3], and intensive care 
units (ICUs) [4]. The incidence of AKI has been increasing over the years, with 
about 2 million people being affected in 2010 [5], despite the efforts of researchers 
and organizations [6–8]. AKI is commonly followed by worse outcomes: prolonged 
length of ICU and hospital stay, need for dialysis, decreases in the glomerular 
filtration rate (GRF), development of chronic kidney disease (CKD), and increases 
in mortality [9–11].
In recent decades, therapeutic interventions aimed at reversing kidney dysfunc-
tion have had disappointing results in multiple settings; thus, the research focus 
has shifted from treatment to prevention and early detection by focusing on two 
main issues: diagnostic criteria and early diagnosis. In 2004, the Acute Dialysis 
Quality Initiative (ADQI) sought a more uniform definition of AKI, and the most 
recent consensus definition was published in 2012 by Kidney Disease: Improving 
Global Outcomes (KDIGO) [8]. The diagnosis of AKI is based on changes in serum 
creatinine (Scr) and urine output (UO), but neither marker is kidney specific. 




The standardization of the diagnosis of AKI allowed us to compare the diagnoses 
made in different settings. However, the issue of early diagnosis is still a challenge. 
First, there are limitations regarding the use of Scr and UO. Second, determining 
the need for renal replacement therapy is difficult due to a lack of information about 
whether the AKI is transient or persistent. Last, the research advances identifying 
early biomarkers have thus far been inaccessible in clinical practice [12].
Neutrophil gelatinase-associated lipocalin (NGAL) [13] has been far and away 
the most promising biomarker to help fill this gap, and its diagnostic capabilities as 
a biomarker have been confirmed in a large number of clinical trials. This chapter 
aims to present information on the role of NGAL in the renal injury process, its 
expression in the kidney, confounding factors, the type of assay used, whether 
plasma or urine NGAL has better accuracy, the cutoff values in normal individuals, 
the accuracy of NGAL for diagnosing AKI, and the evaluation of other outcomes.
2. The role of NGAL
In 1993, Kjeldsen et al. [13] isolated lipocalin as a protease-resistant polypeptide 
covalently bound to neutrophil gelatinase, named neutrophil gelatinase-associated 
lipocalin (NGAL), also known as siderocalin, lipocalin 2 or oncogene 24p [14].
NGAL is a 25 kilodalton (kDa) protein covalently bound to gelatinase in 
neutrophil-specific granules. NGAL is expressed at very low levels in various human 
tissues, including the kidneys, uterus, prostate, salivary gland, trachea, lungs, 
stomach, and adult and fetal colon [15, 16]. The anti-inflammatory function of 
NGAL is demonstrated by increased NGAL expression in proliferative epithelia, 
inflammatory areas, and intestinal malignancies [17].
In normal kidneys, the expression of NGAL is mainly released by the thick 
ascending limb and the intercalated cells of the thick collecting duct. Some NGAL 
expression is also present in the proximal tubular epithelium, once NGAL is filtered 
by the glomerulus and reabsorbed by the proximal tubule in a megalin-dependent 
manner [17, 18]. The physiological function of NGAL in the kidneys is unknown; 
however, the role of NGAL in renal morphogenesis is under consideration [19]. 
NGAL also has a predominant role in the regulation of cell proliferation, repair 
processes, and tubular reepithelization. NGAL expression corresponds to an addi-
tional iron transport pathway, which increases the transcription of hemeoxygenase, 
an enzyme with proliferative and antiapoptotic effects that protects and preserves 
proximal tubular cells [20, 21].
Several biological functions for NGAL have been suggested; in the kidney, 
NGAL release is associated with ischemic or nephrotoxic insults. Additionally, 
a decrease in tubular reabsorption after AKI may lead to a further increase in 
urinary NGAL concentration, resulting acquiring a status of the “troponin” of the 
kidneys [22–24].
KEY POINT: The role of NGAL remains unclear, but its release mainly from the 
distal tubule has been associated with an increase in kidney injury.
3. Confounding factors affecting NGAL
The conditions that can interfere with the performance, sensitivity, and speci-
ficity of NGAL, already identified as a biomarker, are sepsis, chronic obstructive 
pulmonary disease, and cardiac dysfunction, and the presence of these condi-
tions may act as confounding factors for NGAL measurements. The predictive 
performance of NGAL seems to also be influenced by age (higher predictive value 
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in children than in older patients), sex (higher predictive value in female patients 
than in male patients), urinary tract infection, and impaired renal function (higher 
predictive value in patients with chronic kidney disease) [25–27].
Sepsis will be more thoroughly addressed in the next chapter.
KEY POINT. Controlling for confounding factors in clinical trials is vital to maintain 
the internal validity of a study.
4. Types of NGAL assays
The commercialization of NGAL as the gold standard for the diagnosis of AKI is 
somewhat controversial [28]. There are many types of NGAL assays available on the 
market that use different nonautomated ELISA platforms, which makes it difficult 
for comparisons to be made among studies from around the world.
The first kit for the quantitative and automated determination of NGAL by 
the ELISA method was developed by Abbott Laboratories (Abbott Park, IL, USA) 
for the urinary evaluation of NGAL, with a cutoff value of 141 μg/L (95% CI 
125–158 μg/L). An EDTA plasma blood test was created by the Triage Meter plat-
form (Biosite-Inverness Medical, Waltham, USA) with a cutoff value of 163 μ/L (CI 
109–221 μ/L) [29].
Bioporto (Bioporto Diagnostics A/S, Gentfte, Denmark) developed a new particle-
enhanced turbidimetric immunoassay (PETIA) that has the advantages of flexibility 
(adaptation for clinical use in different analyzers), automation (closer to clinical 
practice), and applicability in different biological matrices (urine and plasma) [30].
The chemiluminescence test is an alternative to assess NGAL, and it is com-
monly used to analyze studies with small animals since it is possible to do the 
analysis with few substrates [31].
Because there are three known molecular forms of NGAL, the assay of interest 
should differentiate the 25 kDa NGAL monomer produced by the monocyte tubular 
epithelial cells from other forms of NGAL: 45 kDa NGAL, from the homodimer 
predominantly secreted by neutrophils, and the 145 kDa NGAL/matrix metallopro-
teinase-9 (MMP9) covalently complexed heterodimer [32, 33].
According to Mårtensson et al. [34] and Cai et al. [33], the combination of 
two ELISAs, may improve the diagnostic accuracy of NGAL, one to determine the 
monomeric form and the other to determine the homodimeric form.
The confounding factor of sepsis is described herein and is dependent on the assay 
method, as well as whether the chosen kit is less sensitive to 25 kDa NGAL expressed 
by tubular epithelial cells. The test can also measure the 45 kDa homodimer pre-
dominantly secreted by neutrophils, which are common in sepsis, and the increase in 
neutrophils increases homodimeric NGAL expression and results in false positives.
KEY POINT: Choose a method closer to those used in clinical practice and a test more 
accurate for measuring the monomeric form of NGAL expressed by tubular epithelial 
cells after injury.
5.  Plasma or urine NGAL measurement and normalization of urine 
values
The consensus is clear that NGAL measured in urine has better performance 
[35], because the release and increase in NGAL will occur first in urine. However, 
the collection of urine depends on the urine output, which is sometimes not avail-
able. Some benefits of plasma NGAL are that it is available at any time and is more 
accurate in anuric or oliguric patients.
Inflammation
4
The issue about the normalization of urinary NGAL by correction for the 
urinary creatinine level is debatable, but it has been used to correct for urine output 
in cases of oliguria or pollakiuria, avoiding inaccurate concentration or dilution 
measurements of the biomarkers. The fact is that the creatinine release time is dif-
ferent from the biomarker release time, and the normalized level will be affected by 
this difference and will not represent a real physiological value [36].
KEY POINT: Urinary NGAL is released earlier than plasma NGAL, and the 
accuracy of the normalization of urinary NGAL by creatinine is debatable.
6. Cutoff values of NGAL in normal individuals
The determination of normal NGAL levels in healthy adults has been inad-
equately described in the literature. However, some studies have been performed, 
such as that of Cullen et al. [26], which analyzed urine by the Abbot-Architec assay 
in 174 healthy people (100 men and 74 women aged between 19 and 88 years). The 
value of the immunoassay result was normalized by urinary creatinine, and the 
cut-off value was 107 μ/mmol (13 μ/mmol). There was a higher concentration of 
creatinine-normalized urinary NGAL in women, in the elderly and in patients with 
leukocyturia.
The study reported by Stejkal et al. [37] analyzed BioVendor’s NGAL assay 
using the serum of 136 healthy, nonobese individuals (53 men and 83 women). The 
authors reported median NGAL values (78.8 μg/L for men and 80 μg/L for women). 
Pernnemans et al. [27] analyzed the NGAL ELISA (RD System Europe, Abingdon, 
UK) and other urinary biomarkers in 338 healthy individuals (199 women and 
139 men, aged 0 to 95 years). They reported that the NGAL reference range of the 
21–95 years age group was 73.88–211.16 μg/L in women and 149.26–182.58 μg/L in 
men, and there was higher expression in elderly individuals.
An NGAL PETIA (Bioporto Diagnostics A/S, Gentfte, Denmark) [36] was 
evaluated for 200 healthy nonobese individuals (137 men and 63 women, with a 
mean age of 39 years (SD 11.2)). They proposed reference plasma concentrations 
from 38.7–157.6 ng/ml for women and 24.4–142.5 ng/ml for men and proposed ref-
erence urine concentrations of <9–54.5 ng/ml for both sexes. The authors reported 
that the mean values in men were higher than in women, 78.9 ng/ml vs. 73.8 ng/ml, 
respectively; there was a significant difference in NGAL in relation to age.
In addition to the variability of the chosen immunoassay, the unit of measure-
ment in the interpretation of the NGAL studies should be considered—the most 
commonly found are ng/ml, μg/L, ng/dl, mg/ml and μg/mmol.
KEY POINT: The median cutoff value for urinary NGAL in healthy men was 
between 78.8 and 182.58 μg/L, and the median plasma value was between 24.4 and 
142.5 ng/ml in men. The broad variability of the results difficult to interpret.
7. NGAL to predict AKI
NGAL is the most widely investigated AKI biomarker. Its performance for 
predicting AKI has been evaluated in various settings, such as in pediatric and adult 
cardiac surgery patients, in critically ill patients, and in patients in the emergency 
room, as well in kidney transplant and other settings [38, 39].
Numerous studies have demonstrated the ability of NGAL to diagnose AKI. For 
example, the study reported by Constantin et al. [40], that evaluated the plasma 
NGAL of 88 patients at ICU admission, found a sensitivity of 82%, specificity of 
97% and AUC of 0.92 to cut-off value of 155 mmol/L to predictor of AKI.
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A multicenter study, reported by Di Somma et al. [41], with 665 patients admit-
ted to the emergency department, assessed plasma NGAL in several points after 
admission. Serial evaluation of NGAL at times zero and six hours provided a high 
negative predictive value (NPV) (98%) to rule out the diagnosis of AKI within six 
hours of the arrival of patients to the emergency department. The NGAL value at 
admission could demonstrated a strong predictive value for in-hospital mortality of 
the patient, with a cut-off value of 400 ng/ml.
In the meta-analysis by Haase et al. [42]—with 19 studies, totaling 2538 patients, 
of whom 487 (19.2%) developed AKI—NGAL was demonstrated to have diagnostic 
and prognostic value for AKI, with an OR of 18.6 (95% CI 9–38.1) and AUC of 0.81 
(95% CI 0.73–0.89). The cut-off value ranged from 100 to 270 ng/ml, but a value of 
150 ng/dl was suggested for the diagnosis of AKI.
In another recent meta-analysis by Zhou et al. [39]—with 24 studies, a total of 
4066 patients from 9 countries, including studies with serum and urinary NGAL—
the sensitivity for the diagnosis of AKI was 0.68 (95% CI, 65–0.70), and the speci-
ficity was 0.79 (95% CI 0.77–0.80).
In the study by Singer et al. [38], urinary NGAL was useful for classifying and 
stratifying patients with established AKI: the level of NGAL>104 μg/L indicated 
intrinsic AKI (odds ratio of 5.97), while the level of NGAL <47 μg/L indicated 
unlikely intrinsic AKI (odds ratio of 0.2). In the logistic regression analysis, NGAL 
was able to predict the worsening of the RIFLE class, the need for RRT and in-
hospital mortality. The performance of NGAL to evaluate other outcomes will be 
discussed in the next chapter.
KEY POINT: Despite the good results of NGAL for predicting AKI, the variability of 
the cutoff value is still a challenge for applying NGAL in clinical practice.
8. The early timing diagnosis by NGAL versus standard serum creatinine
The study by Bennett et al. [43] clearly indicated that urinary NGAL is a powerful 
early biomarker of AKI after cardiopulmonary bypass that preceded the increase in 
serum creatinine by 2–3 days. Studies have shown that elevation of NGAL is detect-
able after 3 hours and peaks approximately 6–12 hours after injury. The elevation can 
persist up to 5 days according to the severity of injury [44–46]. In addition to Benett’s 
study, other studies in general have failed to reach conclusions about the early tim-
ing diagnosis of NGAL, which is the main finding required to reach a therapeutic 
window and better evaluate future medication targets in AKI.
KEY POINT: If you perform a study or analyze a biomarker, remember to compare 
the pattern of biomarker early timing diagnosis with serum creatinine.
9. Evaluation of other outcomes by NGAL
Several studies have assessed the diagnostic value of NGAL to predict AKI, but 
only a few have analyzed the early diagnosis in hours/days and compared it with 
serum creatinine, as seen in the last chapter. Still fewer studies have evaluated the 
predictive performance of NGAL in other outcomes, such as the need for RRT, 
recovery of renal function, progression to end stage renal disease (ESRD) and 
mortality, which will be discussed in this chapter.
In the meta-analysis by Hall et al. [47], for 91 kidney transplant patients, the 
incidence of need for RRT was 4.3%, and NGAL, in this scenario, had an OR of 12.9 
and AUC of 0.78. In the same study, NGAL and urinary IL18 were predictors of the 
need for RRT up to 1 week after transplantation. NGAL presented a good AUC of 
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0.81 (95% CI 0.70–0.92) 6 hours after transplantation and was also a predictor of 
graft recovery for up to 3 months.
In the study conducted by Constantin et al. [40], the cutoff value of NGAL to 
assess the need for RRT was 330 mmol/L. The value of urinary NGAL (Architect, 
Abbot Park, IL) was correlated with the need for dialysis (r: 0.48 P: 0.01), presenting 
an AUC of 0.86 2 hours after cardiopulmonary bypass in children [43].
A recent meta-analysis by Klein et al. analyzed 12 studies to predict the need for 
RRT and found an AUC of 0.70 (95% CI 0.63–0.80) for NGAL [48].
Bhavsar et al. [49] concluded that higher levels of NGAL (measured by the 
Luminex assay) were associated with stage 3 CKD incidence. Some researchers 
have discussed whether the association of NGAL level is not exclusively related to 
the increase in neutrophils already described by Tian et al. [50] and maintain that 
further studies would be needed to elucidate this issue.
In the meta-analysis by Haase et al. [42], the incidence of mortality was 5.4%, 
and NGAL, in this scenario, showed an OR of 8.8 and AUC of 0.70.
In the Ariza study [51], PNGAL and UNGAL were demonstrated to be strong 
predictors of prognosis, and UNGAL was significantly predictive of the MELD 
score using the 28-day mortality score AUC of 0.88 (0.83–0.92).
In the study by Bennett et al. [43], the value of urinary NGAL (Architect, Abbot 
Park, IL) was also correlated with mortality (r: 0.53 p 0.01), with an AUC of 0.91, 2 
hours after cardiopulmonary bypass in children.
The study by Dent et al. [52], using PNGAL (Biosite Inc., San Diego, USA) in 120 
children undergoing cardiopulmonary bypass (CBP) and a cut-off value of 150 ng/ml 
and AKI prediction, found an AUC of 0.96 2 hours after CBP. PNGAL was also strongly 
correlated with the duration of AKI (r = 0.57, p < 0.001) and hospital stay time (r = 0.44, 
p < 0.001), and PNGAL at 12 hours was correlated with mortality (r = 0.48, p: 0.004).
In the study by Daniels et al. [53], PNGAL (Alere Inc., Waltham, USA) was mea-
sured in 1393 adult patients with cardiovascular disease (CVD) who were followed 
for 11 years. Of these, 436 did not survive, and 169 died from CVD. PNGAL was a 
predictor of CVD mortality, with a risk ratio of 1.33% and a risk ratio of 1.19% for 
all causes of mortality.
KEY POINT: Evaluating outcomes by NGAL beyond the limitation of only the 
diagnosis of AKI is important to know how more than one parameter evaluates the 
outcome and prognosis, and it could help physicians by indicating an early need for RRT, 
for example.
10. Conclusion
This brief review, based on accumulated evidence, discussed the role and 
value of NGAL in the diagnosis and prognosis of AKI. Studies’ findings suggest 
that induction of NGAL plays an important role in kidney function preservation, 
reducing apoptosis, and enhancing proliferative responses. In kidney injury, rapid 
and massive upregulated synthesis of NGAL occurs in the distal tubule, which 
quickly increases the concentration of NGAL in urine [54]. In addition, other 
important considerations have been provided as “key point” to help researchers 
move the NGAL analysis to clinical practice as soon possible.
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